Meril launches Myval Octapro THV at Global fourms
New
Delhi:
Meril Life Sciences, a leading global med-tech company specializing in
cardiovascular and structural heart solutions, marked a significant milestone
with the launch of its Myval Octapro Transcatheter Heart Valve (THV) at GISE
2024 (National Congress of the Italian Society of Interventional Cardiology)
and PCR London Valves 2024. These esteemed scientific events provided an ideal
platform for Meril to showcase its commitment to advancing structural heart
care.
The
Myval THV series, known for its innovative contributions to transcatheter
aortic valve replacement (TAVR) procedures, continues to set new benchmarks
with the Myval Octapro THV. This latest iteration introduces low frame
foreshortening, enhancing operator control and enabling precise deployment for
improved procedural predictability. Additionally, its comprehensive size
matrix, which includes conventional, intermediate, and extra-large valve sizes,
ensures optimal valve selection tailored to diverse patient anatomies.
Dr. Ashok Seth, Chairman of Fortis Escorts Heart
Institute and Fortis Healthcare Medical council, Delhi
Congratulations
to Meril Life Sciences on the launch of the novel MyvalOctapro. We are proud
Meril has been consistently innovating to set fresh benchmarks in Transcatheter
structural therapies as well as proving them to be safe and effective through
well conducted perspective randomised studies. Octapro THV is next-generation
balloon expandable valve minimal foreshortening to enable precise deployment
and commisural alignment Furthermore, the nine valve sizes (which includes
intermediate sizing and extra-large size) enables accurate and appropriate fit
to patient’s anatomy. In fact, approx. 50% of Myval THV series implants are
intermediate-sized devices, which gives operators a wider options to all
possible annular anatomies
Dr.
Rajneesh Kapoor, Chairman, Interventional Cardiology, Medanta
the Medicity, Gurugram, Haryana
Speaking on this achievement, Sanjeev Bhatt, Senior Vice President of Corporate Strategy at Meril Life Sciences, stated: "The positive reception of the Myval Octapro THV at these global platforms underscores our commitment to delivering cutting-edge solutions for severe aortic stenosis. We are proud to collaborate with clinicians worldwide in advancing TAVR technology and improving patient outcomes through innovation."
At
PCR London Valves 2024, Meril presented key findings from the LANDMARK trial
subset analysis and comparative studies, further establishing the safety and
efficacy of the Myval Transcatheter Heart Valve (THV) series. Published in EuroIntervention
Journal, the findings confirmed the Myval THV’s non-inferiority to both
Sapien and Evolut valve series at 30 days post-implantation, solidifying its
position as a reliable solution for structural heart interventions.
The
results highlighted comparable composite safety and effectiveness outcomes
between Myval and Sapien (24.7% vs. 24.1%), with Myval demonstrating a lower
rate of permanent pacemaker implantation (15.0% vs. 17.3%) and superior
hemodynamic performance. Similarly, the Myval THV series performed on par with
Evolut in composite endpoints (24.7% vs. 30%), while showing advantages in
reducing pacemaker implantation rates and moderate/severe valve regurgitation.
Effective orifice areas were also comparable between 26 and 29 mm of Myval THV
series and Evolut THV series, underscoring its strong performance in key
clinical measures.
The conference also featured the unveiling of the COMPARE-TAVI trial results. Presented by Prof. Henrik Nissen on behalf of the COMPARE-TAVI investigators, this first-of-its-kind randomized controlled trial directly compared the Myval THV series with the Sapien THV series in a real-world, all-comers population.
0 Comments